CA2144648A1 - Retablissement de l'immunocompetence des cellules t auxiliaires chez les sujets infectes par le vih - Google Patents

Retablissement de l'immunocompetence des cellules t auxiliaires chez les sujets infectes par le vih

Info

Publication number
CA2144648A1
CA2144648A1 CA002144648A CA2144648A CA2144648A1 CA 2144648 A1 CA2144648 A1 CA 2144648A1 CA 002144648 A CA002144648 A CA 002144648A CA 2144648 A CA2144648 A CA 2144648A CA 2144648 A1 CA2144648 A1 CA 2144648A1
Authority
CA
Canada
Prior art keywords
antibodies
antagonist
helper cells
interleukin
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002144648A
Other languages
English (en)
Inventor
Mario Clerici
Robert L. Coffman
Gene M. Shearer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Merck Sharp and Dohme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2144648A1 publication Critical patent/CA2144648A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002144648A 1992-09-18 1993-09-16 Retablissement de l'immunocompetence des cellules t auxiliaires chez les sujets infectes par le vih Abandoned CA2144648A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94731692A 1992-09-18 1992-09-18
US07/947,316 1992-09-18

Publications (1)

Publication Number Publication Date
CA2144648A1 true CA2144648A1 (fr) 1994-03-31

Family

ID=25485948

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002144648A Abandoned CA2144648A1 (fr) 1992-09-18 1993-09-16 Retablissement de l'immunocompetence des cellules t auxiliaires chez les sujets infectes par le vih

Country Status (6)

Country Link
EP (1) EP0667789A1 (fr)
JP (1) JPH08501549A (fr)
AU (1) AU4856793A (fr)
CA (1) CA2144648A1 (fr)
MX (1) MX9305713A (fr)
WO (1) WO1994006473A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529026C2 (de) * 1995-07-28 1997-06-19 Robert Sabat Monoklonale Antikörper gegen humanes Interleukin-10
WO1998010792A1 (fr) * 1996-09-11 1998-03-19 Prendergast Patrick T Therapie a but immunitaire
DE19939653A1 (de) * 1999-08-13 2001-02-22 Thomas Huenig Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
DE60138222D1 (de) 2000-09-14 2009-05-14 Beth Israel Hospital Modulierung von il-2 und il-15 vermittelten t zellantworten

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
CZ281796B6 (cs) * 1991-08-06 1997-02-12 Schering Corporation Použití interleukinu-10, jeho analoga, agonisty nebo antagonisty pro výrobu léčiva a farmaceutický přípravek je obsahující

Also Published As

Publication number Publication date
MX9305713A (es) 1994-05-31
JPH08501549A (ja) 1996-02-20
AU4856793A (en) 1994-04-12
EP0667789A1 (fr) 1995-08-23
WO1994006473A1 (fr) 1994-03-31

Similar Documents

Publication Publication Date Title
AU689236B2 (en) Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
Seder et al. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice.
Trembleau et al. Deviation of pancreas‐infiltrating cells to Th2 by interleukin‐12 antagonist administration inhibits autoimmune diabetes
AU690557B2 (en) New therapeutic, anti-proteic mediator kits, a process for their preparation and pharmaceutical compositions containingthem
US20150376278A1 (en) Use of a cd28 binding pharmaceutical substance for making a pharmaceutical composition with dose-dependent effect
EP1793856A2 (fr) Procedes et compositions pour le traitement d'inflammation allergique
Debets et al. Cytokine antagonists and their potential therapeutic use
US8012475B2 (en) Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
Chaturvedi et al. Peptide analogs with different affinities for MHC alter the cytokine profile of T helper cells
Rizzo et al. Regulation of the interaction between Th1 and Th2 T cell clones to provide help for antibody production in vivo
Prümmer Treatment-induced antibodies to interleukin-2
KR20000052800A (ko) 면역 질환을 치료하기 위한 치료제로서의 용해성 림포톡신-베타수용체, 항림포톡신 수용체 항체 및 항림포톡신 리간드 항체
KR100271197B1 (ko) 인터루킨-10동족체또는길항제를포함하는내독소-또는초항원유도된독성치료용의약제학적조성물
CA2144648A1 (fr) Retablissement de l'immunocompetence des cellules t auxiliaires chez les sujets infectes par le vih
JPH07563B2 (ja) 好酸球増加症の予防または鎮静用薬剤
JP3138481B2 (ja) 自己免疫疾患および特にインスリン―依存性糖尿病の治療のためのｉｌ―７の使用
Cunningham-Rundles et al. Immunologic effects of low-dose polyethylene glycol-conjugated recombinant human interleukin-2 in common variable immunodeficiency
Ajitsu et al. In vivo immunologic intervention in age-related T cell defects in murine gut-associated lymphoid tissues by IL2
WO1996040966A1 (fr) Compositions et procedes de traitement de maladies associees a l'interleukine 6 (il-6)
JPH05117163A (ja) 前胸腺細胞の成熟のための医薬製剤
JPH08245414A (ja) Ｉｌ−６関連疾患の治療用組成物および方法
Romball et al. Cytokines in the induction and circumvention of peripheral tolerance

Legal Events

Date Code Title Description
FZDE Dead